Catamaran sell-off yesterday 'puzzling,' says Maxim Maxim views yesterday's pullback in shares of Catamaran as "puzzling" since it says the company reported strong Q3 results and raised its guidance. The firm says Catamaran remains its top pick for 2013 and it recommends buying the stock following yesterdays' weakness.
Catamaran to acquire Salveo Specialty Pharmacy for $260M in cash Catamaran announced that it has entered into a definitive agreement to acquire Salveo Specialty Pharmacy, an independent specialty pharmacy company headquartered in St. Petersburg, Florida with business operations in New York and California. Salveo manages approximately $400M in annual drug spend. The purchase price of $260M in cash represents a purchase price multiple of approximately 13x Salveo's trailing-twelve-month EBITDA and is expected to be funded through cash on the balance sheet. This acquisition is expected to be completed during Q4.